NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free POAI Stock Alerts $1.39 0.00 (0.00%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.5050-Day Range$1.39▼$3.7252-Week Range$1.30▼$7.12Volume14,814 shsAverage Volume23,434 shsMarket Capitalization$5.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Predictive Oncology alerts: Email Address Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Predictive Oncology Stock (NASDAQ:POAI)Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More POAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart POAI Stock News HeadlinesApril 17, 2024 | americanbankingnews.comPredictive Oncology (NASDAQ:POAI) Shares Cross Below 200 Day Moving Average of $3.00April 11, 2024 | finance.yahoo.comPredictive Maintenance Market Worth $47.8 billion by 2029, Growing At a CAGR of 35.1% Report by MarketsandMarkets™April 18, 2024 | Paradigm Press (Ad)AI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.April 2, 2024 | finance.yahoo.comPredictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 Predictive Oncology Inc Earnings CallMarch 31, 2024 | finance.yahoo.comPredictive Oncology Full Year 2023 Earnings: US$3.48 loss per share (vs US$7.05 loss in FY 2022)March 29, 2024 | finanznachrichten.dePredictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarketsMarch 29, 2024 | finance.yahoo.comPredictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarkets™April 18, 2024 | Paradigm Press (Ad)AI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.March 29, 2024 | msn.comPredictive Oncology GAAP EPS of -$3.48, revenue of $1.78MMarch 29, 2024 | investorplace.comPOAI Stock Earnings: Predictive Oncology Reported Results for Q4 2023March 28, 2024 | globenewswire.comPredictive Oncology Reports Year End 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | finance.yahoo.comWorldQuant Predictive Appoints Amir Husain as Chairman of the BoardFebruary 24, 2024 | msn.comPredictive tests: How accurate?February 21, 2024 | finance.yahoo.comPredictive Oncology to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | globenewswire.comPredictive Oncology to Participate in Upcoming Investor ConferencesFebruary 9, 2024 | msn.comPredictive Oncology Announces Chief Business Officer TransitionFebruary 3, 2024 | finance.yahoo.comGlobal Predictive Analytics Market: Forecasts Significant Growth Through 2030February 1, 2024 | finance.yahoo.comPoint Predictive Fortifies Auto Dealership Business Line, Inks Deals Bringing on Hundreds of RooftopsFebruary 1, 2024 | es-us.finanzas.yahoo.comInsights-as-a-Service Market Forecast Shows Strong Growth with Predictive Analysis Leading the ChargeJanuary 30, 2024 | finance.yahoo.comGlobal Industrial Analytics Market Forecast 2024-2030: Predictive Analytics Segment Showing Strong Upsurge through 2030November 14, 2023 | finanznachrichten.dePredictive Oncology Inc.: Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 14, 2023 | proactiveinvestors.comPredictive Oncology 'pleased with progress' as it delivers 3Q resultsNovember 14, 2023 | msn.comPredictive Oncology GAAP EPS of -$0.78, revenue of $0.72MNovember 14, 2023 | finance.yahoo.comPredictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 10, 2023 | morningstar.comPredictive Oncology Inc POAINovember 8, 2023 | proactiveinvestors.comPredictive Oncology completes AI-driven cancer study with UPMC Magee-Womens HospitalSee More Headlines Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today4/17/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-785.62% Pretax Margin-785.62% Return on Equity-104.21% Return on Assets-70.49% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.43 Sales & Book Value Annual Sales$1.78 million Price / Sales3.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.68Miscellaneous Outstanding Shares4,060,000Free Float3,923,000Market Cap$5.64 million OptionableNot Optionable Beta1.28 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Raymond F. Vennare (Age 72)CEO & Chairman Comp: $581.58kMr. Joshua Blacher M.B.A. (Age 51)Interim Chief Financial Officer Ms. Theresa FergusonSenior Director of MarketingDr. Lawrence J. DeLucas D.ScO.D, Ph.D., Senior Vice President of BiologicsDr. Arlette H. Uihlein FCAPM.D., Senior VP of Translational Medicine & Drug Discovery and Medical DirectorKey CompetitorsHeart Test LaboratoriesNASDAQ:HSCSNanoVibronixNASDAQ:NAOVTitan MedicalNASDAQ:TMDIFXWELLNASDAQ:XWELAvingerNASDAQ:AVGRView All CompetitorsInsiders & InstitutionsCarnegie Mellon UniversityBought 10,358 shares on 2/2/2024Ownership: 0.255%Charles Lee Sr Nuzum SrSold 10,000 sharesTotal: $30,400.00 ($3.04/share)View All Insider TransactionsView All Institutional Transactions POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed in 2024? Predictive Oncology's stock was trading at $3.29 at the beginning of the year. Since then, POAI stock has decreased by 57.8% and is now trading at $1.39. View the best growth stocks for 2024 here. Are investors shorting Predictive Oncology? Predictive Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 25,500 shares, an increase of 129.7% from the March 15th total of 11,100 shares. Based on an average trading volume of 23,600 shares, the short-interest ratio is presently 1.1 days. Approximately 0.7% of the shares of the company are sold short. View Predictive Oncology's Short Interest. When is Predictive Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our POAI earnings forecast. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings data on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.60. The medical instruments supplier earned $0.35 million during the quarter, compared to analyst estimates of $0.80 million. Predictive Oncology had a negative trailing twelve-month return on equity of 104.21% and a negative net margin of 785.62%. When did Predictive Oncology's stock split? Predictive Oncology shares reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE). How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:POAI) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressOptions trading has suddenly become more reliable.Eagle PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.